IDROCILAMIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H13NO2
Molecular Weight	191.2264
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0
Stereo Comments	Assumed E; MM2 minimum energies of E and Z were -2.8973 and 2.1467/ 1.3201 kcal/mol respectively.

SHOW SMILES / InChI

Structure Search

SMILES

OCCNC(=O)\C=C\C1=CC=CC=C1

InChI

InChIKey=OSCTXCOERRNGLW-VOTSOKGWSA-N

InChI=1S/C11H13NO2/c13-9-8-12-11(14)7-6-10-4-2-1-3-5-10/h1-7,13H,8-9H2,(H,12,14)/b7-6+

HIDE SMILES / InChI

Molecular Formula	C11H13NO2
Molecular Weight	191.2264
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3985591
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/idrocilamide.html | https://www.ncbi.nlm.nih.gov/pubmed/2140002 | https://www.ncbi.nlm.nih.gov/pubmed/8180884 | https://www.ncbi.nlm.nih.gov/pubmed/8012322

Idrocilamide (trade names Talval, Srilane, Relaxnova, Brolitène) is a medication with skeletal muscle relaxant[2] and anti-inflammatory actions used as a topical cream to treat lumbago and other kinds of muscular pain. Idrocilamide acts intracellularly by decreasing sarcoplasmic reticulum calcium release and externally by facilitating the voltage-dependent inactivation of the voltage sensor for excitation-contraction coupling. Idrocilamide has been reported to be a potent inhibitor of the metabolism of caffeine. Idrocilamide is available on prescription or over-the-counter in France and various other countries. Idrocilamide exerts a direct depressant effect on mechanical tension in rat soleus muscle fibers.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
release of sequestered calcium ion into cytosol by sarcoplasmic reticulum 1 Target ID: GO:0014808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8180884	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute lumbago 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2140002	Primary		Approved 8583	Talval Approved Use Unknown

T_1/2

Value	Dose	Analyte	Population
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7192119/	60 mg single, intravenous dose: 60 mg route of administration: Intravenous experiment type: SINGLE co-administered:	IDROCILAMIDE serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7192119/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	IDROCILAMIDE serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7192119/	400 mg single, topical dose: 400 mg route of administration: Topical experiment type: SINGLE co-administered:	IDROCILAMIDE serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 2 times / day multiple, topical Highest studied dose Dose: 200 mg, 2 times / day Route: topical Route: multiple Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8012322/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8012322/	Sources: https://pubmed.ncbi.nlm.nih.gov/8012322/
60 mg single, intramuscular Highest studied dose Dose: 60 mg Route: intramuscular Route: single Dose: 60 mg Sources: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.410170119	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.410170119	Sources: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.410170119
5 % 1 times / day multiple, topical Recommended Dose: 5 %, 1 times / day Route: topical Route: multiple Dose: 5 %, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-201012840-00094	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://link.springer.com/article/10.2165/00128415-201012840-00094	Disc. AE: Generalised exfoliative dermatitis... AEs leading to discontinuation/dose reduction: Generalised exfoliative dermatitis Sources: https://link.springer.com/article/10.2165/00128415-201012840-00094
1200 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	Other AEs: Tiredness, Vomiting... Other AEs: Tiredness (14.3%) Vomiting (14.3%) Giddiness (9.5%) Depression (9.5%) Muscle stiffness (9.5%) Nausea (4.8%) Dystonia (4.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/788760/

AEs

AE	Significance	Dose	Population
Generalised exfoliative dermatitis	Disc. AE	5 % 1 times / day multiple, topical Recommended Dose: 5 %, 1 times / day Route: topical Route: multiple Dose: 5 %, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-201012840-00094	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://link.springer.com/article/10.2165/00128415-201012840-00094
Tiredness	14.3%	1200 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/788760/
Vomiting	14.3%	1200 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/788760/
Dystonia	4.8%	1200 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/788760/
Nausea	4.8%	1200 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/788760/
Depression	9.5%	1200 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/788760/
Giddiness	9.5%	1200 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/788760/
Muscle stiffness	9.5%	1200 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/788760/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/788760/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP19A1 429 CYP2C19 2057

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1550874#section=BioAssay-Results Page: 6.0	inconclusive [IC50 12.3018 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1550874#section=BioAssay-Results Page: 4.0	inconclusive [IC50 8.709 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1550874#section=BioAssay-Results Page: 58.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1550874#section=BioAssay-Results Page: 5.0	yes [IC50 11.4657 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1550874#section=BioAssay-Results Page: 7.0	yes [IC50 15.4871 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1550874#section=BioAssay-Results Page: 2.0	yes [IC50 5.495 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1550874#section=BioAssay-Results Page: 9.0

PubMed

Title	Date	PubMed
Two sites of action for LCB29 (idrocilamide) in depressing mechanical tension of rat soleus muscle fibers?	1993-12	8180884
The direct depressant effect of LCB29 (idrocilamide) on mechanical tension of rat soleus muscle fibers.	1990-12	2085796

Patents

Sample Use Guides

In Vivo Use Guide

Single administration - 60 mg

Route of Administration: Intramuscular

In Vitro Use Guide

Experiments were performed at 37C on small bundles (5- 15 fibers) isolated from sealeus nrauscles of female Wistar rats. Before each set of experiments, the preparations were stimulated in the control solution during 20 min or more tea check for viability (those bundles exhibiting progressive decrease in twitch amplitude were discarded). Caffeine contrackres were elicited by application of caffeine added to the bathing medium to give a final concentration of 6 mkM. Such a caffeine concentration permitted repetitive contractures without damaging fibers After the initial equilibrating perid, the sensitivity of bundles for 6 mkM caffeine was checked two times, separated by a 30-min interval in which caffeine was absent. Only bundles that exhibited two successive contractures of equal amplitude were further tested with LCB29 (Idrocilamide).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:58:16 GMT 2025` Edited by `admin` on `Mon Mar 31 17:58:16 GMT 2025`
Record UNII	6C816LUB1O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SRILANE

Preferred Name

English

IDROCILAMIDE

Official Name

English

IDROCILAMIDE [MART.]

Common Name

English

NSC-63229

Code

English

idrocilamide [INN]

Common Name

English

NSC-58207

Code

English

NSC-44979

Code

English

Idrocilamide [WHO-DD]

Common Name

English

N-(2-HYDROXYETHYL)CINNAMAMIDE

Systematic Name

English

IDROCILAMIDE [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM02AX05